Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial.
Of 1078 patients admitted to the coronary care unit with acute chest pain, 293 who had possible acute myocardial infarction and symptoms of median 4 h duration were randomized to treatment with acetylsalicylic acid (ASA) 100 mg daily, 1000 mg daily or placebo for 3 months. During hospitalization, the combined incidence of cardiac death and non-fatal myocardial infarction on-treatment (withdrawals not included) was significantly lower (P less than 0.02) in the 100 mg group (7.1%) than in both the 1000 mg group (20.8%) and the placebo group (19.7%). During later time periods of treatment and at all time periods analysed according to the intention-to-treat principle (withdrawals included), data suggested the same trend, but differences were not statistically significant. Collagen-induced platelet aggregation and serum thromboxane B2 were reduced to the same degree in the two ASA groups and were normal in the placebo group. The data suggest that low-dose ASA could be cheap and safe as first-aid therapy in myocardial infarction suspects.
Husted
S E
SE
Department of Internal Medicine and Cardiology, Aarhus Amtssygehus, University Hospital, Denmark.
Kraemmer Nielsen
H
H
Krusell
L R
LR
Faergeman
O
O
D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003402:Creatine Kinase / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D010919:Placebos; D010974:Platelet Aggregation / Q000187:drug effects; D011897:Random Allocation; D013929:Thromboxane B2 / Q000097:blood*
D010919:Placebos; D013929:Thromboxane B2; D003402:Creatine Kinase; D001241:Aspirin